ライフサイエンスコーパス: malignant potential

1 alignant potential) or oncogenes (activating malignant potential).

2 -grade lymphoma in one patient indicates the malignant potential.

3 lial and stromal overgrowth but have limited malignant potential.

4 ast, are heterogeneous with respect to their malignant potential.

5 or metastatic behavior and indicators of low malignant potential.

6 with Stat3 activation being correlated with malignant potential.

7 heterogeneous group of lesions with diverse malignant potential.

8 or metastatic behavior and indicators of low malignant potential.

9 initiation occurs is a major determinant of malignant potential.

10 her the tumor has hormonal activity, and its malignant potential.

11 tal hyperplasia is a lesion with significant malignant potential.

12 cystic lesions of the liver which carry pre-malignant potential.

13 l histological subtypes except tumors of low malignant potential.

14 and suggest that the difference may reflect malignant potential.

15 rade 2, 2 were of grade 1, and 3 were of low malignant potential.

16 nge due to their morphological diversity and malignant potential.

17 nd pancreatic fluid collections, do not have malignant potential.

18 sets of colorectal serrated polyps (SP) have malignant potential.

19 sets of colorectal serrated polyps (SP) have malignant potential.

20 certain types are associated with increased malignant potential.

21 d', with subclone mixing indicative of early malignant potential.

22 n before neoplasms have invaded and acquired malignant potential.

23 gical indicators of higher proliferative and malignant potential.

24 e development of lesions, some of which have malignant potential.

25 equently, thereby increasing tumorigenic and malignant potential.

26 its indolent clinical behavior and uncertain malignant potential.

27 nt for invading cancers and to augment their malignant potential.

28 cytokines may identify those cysts with high malignant potential.

29 with no malignant potential from those with malignant potential.

30 llary neoplasms (SPN), a rare tumor with low malignant potential.

31 hemotherapy and yielded tumors with enhanced malignant potential.

32 s rise to a population of cells with greater malignant potential.

33 all carcinoid tumors and all carcinoids have malignant potential.

34 cyte hyperplasia without invasiveness or pre-malignant potential.

35 endocrine tumors that occur in MEN 1 carry a malignant potential.

36 may be associated with pancreatitis or have malignant potential.

37 mpared with similar-sized adenomas that have malignant potential.

38 cystic neoplasms of the pancreas with clear malignant potential.

39 d neoplasms were benign or of a low grade of malignant potential.

40 ically heterogeneous neoplasms with variable malignant potential.

41 ll for its activity can greatly reduce their malignant potential.

42 d-stage ovarian cancer (III/IV)], 6 of 6 low malignant potential, 5 of the 6 benign tumors, and 9 of

43 , and SSPs accounted for 9.4% of polyps with malignant potential (95% CI, 6.6-12.3).

44 By comparing cells with high and low malignant potential alongside their nontransformed count

45 this region, including 3 of 7 tumors of low malignant potential and 4 of 5 nonmetastatic carcinomas.

46 distinct EBV variants may have an increased malignant potential and are thus more likely to induce E

47 vels, are associated with both tumors of low malignant potential and carcinomas but not with cystaden

48 he reasons why HPPs with KRAS mutations lack malignant potential and compared the effects of Kras/KRA

49 disease (VHL) is challenging because of the malignant potential and difficulty in predicting prognos

50 24 patients, eight biomarker candidates for malignant potential and high-grade dysplasia/cancer were

51 rticle reviews 'classic' genodermatoses with malignant potential and highlights recent recommendation

52 ancers <3 cm in diameter behave with minimal malignant potential and likelihood of transmission to th

53 cystic pancreatic endocrine neoplasms, have malignant potential and must be surveyed.

54 Notably, the degree of malignant potential and natural history of the most comm

55 In patients, Shc expression correlated with malignant potential and overall survival.

56 umours has led to speculation that they lack malignant potential and represent a biological entity di

57 sm or mucinous cystic neoplasm) lesions have malignant potential and should be distinguished from ser

58 S thyroid tumors could provide insights into malignant potential and tumor progression to help optimi

59 for accurate typing of the polyps to predict malignant potential and underlying possible genetic abno

60 rd that assumed that all polyps >/=10 mm had malignant potential and were considered neoplastic or hi

61 (benign), atypical Spitz tumor (intermediate malignant potential), and spitzoid melanoma (fully malig

62 eterogeneous neuroendocrine tumors that have malignant potential, and are most commonly found in the

63 atic mucinous cystic neoplasms (MCNs) harbor malignant potential, and current guidelines recommend re

64 erine cancer, uterine neoplasms of uncertain malignant potential, and endometrial hyperplasia were es

65 r histopathological presentation and limited malignant potential--and place Lkb1 in a distinct class

66 n approach is that indolent lesions with low malignant potential are common, and screening brings ind

67 Tumors of varying malignant potential arise from the complex epithelial li

68 vironment are enabled to fully express their malignant potential as evidenced by the alpha6beta4 inte

69 eatic cysts requires risk stratification for malignant potential based on the presence or absence of

70 ulation was observed in PDAC compared to low malignant potential BCT.

71 utaneous stigmata of the genodermatoses with malignant potential can lead to early diagnosis and init

72 d 41 melanocytic proliferations of uncertain malignant potential, classified based on interobserver r

73 Thus, histologically benign or low malignant potential components found in heterogeneous ov

74 ploidy in both histologically benign and low malignant potential components.

75 ncer cell lines is associated with decreased malignant potential, confirming its important driver rol

76 n each individual patient, in terms of their malignant potential, drug sensitivity, and their potenti

77 groups of ovarian tissues reflective of low malignant potential/early cancer onset and possible pre-

78 r pylori-related tumor of B-cell origin, the malignant potential for which remains to be defined in i

79 nding lesions with difficult-to-characterize malignant potential (for example, intraductal papillary

80 learly distinguishing cystic lesions with no malignant potential from those with malignant potential.

81 patients (including those with tumors of low malignant potential) had stage I disease, 5 had stage IV

82 mixing genetically marked keratinocytes with malignant potential (II-4) with normal keratinocytes at

83 ansion of co-evolving subclones with similar malignant potential in absence of late bottlenecks and s

84 ALL cells in vitro and dramatically inhibits malignant potential in an in vivo mouse model.

85 CD44 expression is associated with enhanced malignant potential in esophageal squamous cell carcinom

86 tegrin and FAK significantly correlates with malignant potential in patients with triple-negative bre

87 lanomas using clinical factors predictive of malignant potential, in keeping with similar philosophy

88 changes in expression of putative markers of malignant potential, including p53, cyclin D1, and Ki-67

89 However, assessment of malignant potential is desirable for choice of treatment

90 which the identification of factors endowing malignant potential is strongly warranted.

91 thelial ovarian tumors [16 classified as low malignant potential (LMP) and 66 classified as primary o

92 aining benign ovarian tumors, borderline/low malignant potential (LMP) ovarian tumors as well as inva

93 Papillary serous low malignant potential (LMP) tumors are characterized by ma

94 ve epithelial ovarian carcinoma, 30 with low malignant potential (LMP) tumors, 16 with benign tumors,

95 ly stage) and 25 patients with tumors of low malignant potential (LMP).

96 Since a small percentage of PCNs possess malignant potential, management is challenging.

97 mas (MAs) and ovarian mucinous tumors of low malignant potential (MLMPs) unassociated with PMP.

98 sive carcinomas compared with benign and low malignant potential neoplasms (P = 0.007), but no signif

99 g clonal selection in Barrett's and that the malignant potential of 'benign' Barrett's lesions is pre

100 Diminished malignant potential of Adp27KIP1-infected cells was mani

101 We aimed to assess the malignant potential of appendiceal NETs of 1-2 cm in siz

102 As the enhanced malignant potential of cancer cells after nonlytic cogna

103 The malignant potential of cancer is dynamic, changing throu

104 e mechanisms by which c-erbB-2 increases the malignant potential of cells remains unclear.

105 enetic events associated with the origin and malignant potential of FTH are poorly understood.

106 adhesion molecule 1 (CEACAM1) expression and malignant potential of gastric cancer and to address whe

107 We show that Mig-6 quells the malignant potential of GBM cells and dampens EGFR signal

108 s that can be used to predict accurately the malignant potential of histological prostate cancers.

109 ivin expression is associated with increased malignant potential of human gliomas.

110 Given the uncertainty in estimating the true malignant potential of IPMNs, a better understanding of

111 hibition of IL-23p19 was shown to reduce the malignant potential of lesions established by MCA inocul

112 shown previously to correlate with enhanced malignant potential of many human tumor types, including

113 lanocytes and are reported to exacerbate the malignant potential of melanomas.

114 d the underlying biological basis for higher malignant potential of mixed-type IPMNs.

115 Genomic approaches to characterize the malignant potential of nodules showed initial promise bu

116 xtinction of the derived lineages, halts the malignant potential of one of the most aggressive forms

117 e DAXX/ATRX molecular machinery increase the malignant potential of panNETs, and that identification

118 Although the malignant potential of PIN IV in mice has not been prove

119 d also provides a critical constraint to the malignant potential of Rb mutant tumor cells.

120 PAR2-derived MV induces EMT and enhances the malignant potential of recipient cells.

121 s been studied as a tool to help predict the malignant potential of sarcomas, prognosis of patients a

122 egree of angiogenesis is correlated with the malignant potential of several cancers, including breast

123 The malignant potential of smooth muscle tumors correlates s

124 Nevertheless, the malignant potential of SSIM cells remains undetermined.

125 ing technique for clinical evaluation of the malignant potential of the bile duct.

126 ose of typical surface Barrett's glands, the malignant potential of the buried glands, especially whe

127 The molecular basis for the malignant potential of the HGF/SF-Met signal in cancer c

128 Here, we have investigated the malignant potential of the high-grade PIN lesions that f

129 whereas native NRG stimulation increased the malignant potential of the same cells.

130 spectrum between normal differentiation and malignant potential of these cells reflects the dynamic

131 a valuable technology for identification of malignant potential of thyroid nodules.

132 Our results argue that the low malignant potential of tumors arising from TSC1-2 dysfun

133 s and abnormal gene expression, increase the malignant potential of tumors by affecting pathways that

134 thodologies for using nucleoli to assess the malignant potential of uveal melanoma.

135 CEACAM1 is associated with malignant potential of various cancers.

136 To investigate the malignant potential of viable circulating carcinoma cell

137 ed risk of early-onset adenomas with greater malignant potential (OR(Q4 vs Q1), 1.65 for villous/tubu

138 As can work as tumor suppressors (inhibiting malignant potential) or oncogenes (activating malignant

139 hologic finding (cancer, tumors of uncertain malignant potential, or endometrial hyperplasia) were 0.

140 le of chromosomal instability in determining malignant potential over a broad range of tumors.

141 Melanoma cells with high malignant potential (PDGFR-positive, c-Kit-negative) or

142 tial (PDGFR-positive, c-Kit-negative) or low malignant potential (PDGFR-positive, c-Kit-positive) wer

143 Its malignant potential places careproviders in a clinical d

144 atellite loci from colorectal polyps without malignant potential (PWOMP), precancers, and early-stage

145 rian tumors (BOTs), or ovarian tumors of low malignant potential, represent a distinct category of ep

146 d patient thyroids with varying fibrotic and malignant potential revealed discrete variations in STFN

147 elation, and these Spitz tumors of uncertain malignant potential should be excised with 5 mm margins.

148 levels of EP4 influence important markers of malignant potential, such as anchorage-independent growt

149 PTs) are unusual pancreatic neoplasms of low malignant potential that most frequently affect young wo

150 like cell population in NSCLC with increased malignant potential, the elucidation of which may enable

151 modulate the morphology of the tumor and its malignant potential through mechanical, biochemical, gen

152 used ovarian epithelial tumors of different malignant potential to look for associations between 5'-

153 ies the gene regulatory network that confers malignant potential to neural tumors with early developm

154 on of this gene in 44 ovarian tumors (12 low malignant potential tumors and 32 carcinomas) and 10 nor

155 n were significantly elevated in 7 of 12 low malignant potential tumors and in 27 of 32 carcinomas.

156 ificantly with a risk of ovarian cancer (low malignant potential tumors OR, 0.85; 95% CI, 0.79-0.91;

157 udies suggest that ovarian cystadenomas, low malignant potential tumors, and carcinomas are not part

158 ncer (22,406 cases; 40,941 controls) and low malignant potential tumours (3,103 cases; 40,941 control

159 In analyses examining histotypes and low malignant potential tumours, the strongest associations

160 pithelial ovarian cancer histotypes, and low malignant potential tumours.

161 lts The optimal set of markers for detecting malignant potential was a panel of peptides from mucin-5

162 (cSCC), the most frequent skin neoplasm with malignant potential, we have developed an integrated app

163 )-positive cells, suggesting that cells with malignant potential were eliminated from the tissue at t

164 ive in the detection of lesions that have no malignant potential when compared with similar-sized ade

165 at imaging as benign subtypes or those with malignant potential, while others remain indeterminate.

166 ich exhibits low expression of GRO-alpha and malignant potential with a pActin-KC vector encoding mGR

167 c benign cystic tumors (BCT) of low and high malignant potential with PDAC, in order to identify miRN